Choices, Choices

At Motley Fool, Brian Orelli sizes up both Pacific Biosciences and Complete Genomics to determine which one is the "better buy." Orelli notes that some analysts are skeptical about sequencing's prospects, though he isn't since there is a demand for sequencing and because "the bust [is] still many years away." As for choosing between the two companies, Orelli says, "It's too early to make a definitive call, but of the two, I like PacBio better because I'

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.